ArticleJournal of clinical laboratory analysis2025
Optimizing Markers for Chronic Lymphocytic Leukemia Diagnosis by Flow Cytometry: Results From the Nationwide Thai Lymphoma Study Group.
Article in Journal of clinical laboratory analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
introductionAccurate diagnosis of chronic lymphocytic leukemia (CLL) is crucial for effective management. Although recent advancements in flow cytometry have significantly improved diagnostic accuracy, distinguishing atypical cases of CLL remains challenging. This study aimed to identify specific markers to enhance CLL diagnosis and prognostic assessment.
methodsBlood or bone marrow from patients presenting with persistent lymphocytosis (> 5 × 10
resultsA total of 228 patients were included in the study, including 206 patients (90.4%) in the CLL group and 22 patients (9.6%) in the non-CLL group. The use of CD5, CD19, and CD200 in combination for diagnosing CLL demonstrated a sensitivity of 82.5% (95% CI, 76.6-87.4) and a specificity of 90.9% (95% CI, 70.8-98.9). In the final predictive model, which incorporated five markers (CD5, CD19, CD200, CD31, and CD11c), both specificity and positive predictive value for CLL diagnosis were close to 100% (95% CI, 84.6-100 and 95.5-100, respectively). CD38 was identified as an independent predictor of increased relapse risk, while LAIR expression was associated with a reduced relapse rate.
conclusionExpression of CD5, CD19, and CD200 by flow cytometry demonstrated a highly sensitive and accurate diagnostic utility for CLL. Adding both CD31 and CD11c to the predictive model further improved diagnostic specificity, reaching as high as 100%. The identification of relapse-associated markers provides valuable insights for personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.